Company Information

  

Address: 281 ALBANY STREET  
City: CAMBRIDGE 
State: MA 
Zip Code: 02139 
Telephone: 617-995-0900 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company that is focused on developing and commercializing a novel class of therapeutics called stapled peptides. Our lead product candidate, ALRN-6924, targets the tumor suppressor p53 for the treatment of a wide variety of cancers. ALRN-6924, which is currently being tested in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting the two primary p53 suppressor proteins, MDMX and MDM2. Our ongoing clinical trials of ALRN-6924 consist of a Phase 1 trial for the treatment of advanced solid tumors or lymphomas, a Phase 2a trial for the treatment of peripheral T-cell lymphoma, or PTCL, a Phase 1 trial for the treatment of acute myeloid leukemia, or AML, and advanced myelodysplastic syndrome, or MDS, as a monotherapy and a Phase 1b trial for the treatment of AML/MDS in combination with cytosine arabinoside, or Ara-C.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/201817.36NA0.31
03/20187.02NA1.16
12/2017-3.04NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.12Total Liab/Total Assets0.09
Net Inc/Total Assets-0.43Total Liab/Inv Cap0.10
Net Inc/Inv Cap-0.47Total Liab/Comm Equity0.03
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio10.60
Inventory TurnoverNACurrent Ratio10.60
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2018 3/31/2018 12/31/2017 9/30/2017
Total Revenues(Net Sales) 0.00 0.00 0.00 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 4.34 2.92 2.73 2.60
Operating Income -9.66 -7.76 -7.04 -6.43
Interest Exp NA NA NA NA
Pretax Income -9.49 -7.59 -6.87 -6.26
Other Income 0.17 0.18 0.18 0.17
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -9.49 -7.59 -6.87 -6.26

Balance Sheet (Millions)

Assets 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Cash & Short Term Investments 35.82 43.38 50.84 56.95
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 37.21 44.45 51.84 58.12
Net Property, Plant & Equipment 4.12 0.13 0.15 0.11
Total Assets 42.58 45.83 52.69 59.04
Liabilities        
Accounts Payable 6.36 4.86 4.89 5.02
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 6.36 4.86 4.89 5.02
Long-Term Debt NA NA NA NA
Total Liabilities 9.71 4.86 4.89 5.02
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.02 0.02 0.02 0.02
Retained Earnings -154.03 -144.53 -136.95 -130.08
Treasury Stock NA NA NA NA
Total Stockholders' Equity 32.87 40.98 47.80 54.01
Total Liabilities and Stockholders' Equity 42.58 45.83 52.69 59.04

Cash Flow Summary (Millions)

Categories 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Net Cash Provided by Operating Activities -7.46 -6.93 -5.84 -5.24
Net Cash Provided by Investing Activities 12.58 2.40 4.52 -41.44
Net Cash Provided by Financing Activities 0.01 0.02 -0.24 50.70

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20150.00-12.88--
12/20160.00-18.12--
12/20170.00-22.60-3.04
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18359256.28




Report Date : 9/24/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.